keyword
https://read.qxmd.com/read/38688945/characterization-of-macrophages-in-head-and-neck-squamous-cell-carcinoma-and-development-of-mrg-based-risk-signature
#21
JOURNAL ARTICLE
Lei Liu, Qiang Liu
Macrophages are immune cells in the TME that can not only inhibit angiogenesis, extracellular matrix remodeling, cancer cell proliferation, and metastasis but also mediate the phagocytosis and killing of cancer cells after activation, making them key targets in anti-tumor immunotherapy. However, there is little research on macrophages and their relation to disease prognosis in HNSCC. Initially, we collected scRNA-seq, bulk RNA-seq, and clinical data. Subsequently, we identified macrophages and distinguished MRGs...
April 30, 2024: Scientific Reports
https://read.qxmd.com/read/38687975/localized-sustained-release-of-copper-enhances-antitumor-effects-of-disulfiram-in-head-and-neck-cancer
#22
JOURNAL ARTICLE
Juan Wang, Boxuan Li, Remy C Cooper, Da Huang, Hu Yang
Drug repurposing uses approved drugs as candidate anticancer therapeutics, harnesses previous research and development efforts, and benefits from available clinically suitable formulations and evidence of patient tolerability. In this work, the drug used clinically to treat chronic alcoholism, disulfiram (DSF), was studied for its antitumor efficacy in a copper-dependent manner. The combination of DSF and copper could achieve a tumor cell growth inhibition effect comparable to those of 5-fluorouracil and taxol on head and neck cancer cells...
April 30, 2024: Biomacromolecules
https://read.qxmd.com/read/38686795/germline-cis-variant-determines-epigenetic-regulation-of-the-anti-cancer-drug-metabolism-gene-dihydropyrimidine-dehydrogenase-dpyd
#23
JOURNAL ARTICLE
Ting Zhang, Alisa Ambrodji, Huixing Huang, Kelly J Bouchonville, Amy S Etheridge, Remington E Schmidt, Brianna M Bembenek, Zoey B Temesgen, Zhiquan Wang, Federico Innocenti, Deborah Stroka, Robert B Diasio, Carlo R Largiadèr, Steven M Offer
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU...
April 30, 2024: ELife
https://read.qxmd.com/read/38686567/hepatic-arterial-infusion-chemotherapy-lenvatinib-plus-programmed-cell-death-protein-1-inhibitors-a-promising-treatment-approach-for-high-burden-hepatocellular-carcinoma
#24
JOURNAL ARTICLE
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) has demonstrated remarkable local therapeutic efficacy in treating patients with large unresectable hepatocellular carcinoma (HCC). Additionally, the combination of lenvatinib and programmed cell death protein-1 (PD-1) inhibitors has demonstrated promising antitumor effects in unresectable HCC. Therefore, we conducted a retrospective analysis to evaluate the efficacy and safety of combining HAIC with lenvatinib and PD-1 inhibitors as a first-line therapeutic approach in high-burden HCC patients...
May 2024: Cancer Medicine
https://read.qxmd.com/read/38685795/high-throughput-bioprinting-using-decellularized-adipose-tissue-based-hydrogels-for-3d-breast-cancer-modeling
#25
JOURNAL ARTICLE
Priyanshu Shukla, Ashis Kumar Bera, Sriya Yeleswarapu, Falguni Pati
3D bioprinting allows rapid automated fabrication and can be applied for high throughput generation of biomimetic constructs for in vitro drug screening. Decellularized extracellular matrix (dECM) hydrogel is a popular biomaterial choice for tissue engineering and studying carcinogenesis as a tumor microenvironmental mimetic. This study proposes a method for high throughput bioprinting with decellularized adipose tissue (DAT) based hydrogels for 3D breast cancer modeling. A comparative analysis of decellularization protocol using detergent-based and detergent-free decellularization methods for caprine-origin adipose tissue is performed, and the efficacy of dECM hydrogel for 3D cancer modeling is assessed...
April 29, 2024: Macromolecular Bioscience
https://read.qxmd.com/read/38685385/knocking-down-of-xkr8-enhances-chemotherapy-efficacy-through-modulating-tumor-immune-microenvironment
#26
JOURNAL ARTICLE
Yuang Chen, Chien-Yu Chen, Haozhe Huang, Zhangyi Luo, Yiqing Mu, Shichen Li, Song Li
Scramblase Xk-related protein 8 (Xkr8) regulates the externalization of phosphatidylserine (PS) during apoptosis and holds a pivotal role in fostering tumor immunosuppression. Targeting Xkr8 in conjunction with chemotherapy demonstrated a novel avenue for amplifying antitumor immune response and overcoming chemo-immune resistance. Here we further evaluated this strategy by using a clinically relevant orthotopic model and elucidated the mechanism through in-depth single-cell RNA sequencing (scRNA-seq). We found that Xkr8 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clearance of apoptotic cells...
April 27, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38684755/identification-of-panoptosis-related-biomarkers-and-analysis-of-prognostic-values-in-head-and-neck-squamous-cell-carcinoma
#27
JOURNAL ARTICLE
Ping Yang, Guangzhao Huang, Yulin Li, Lang Yu, Zili Yin, Qian Li
PANoptosis plays a crucial role in cancer initiation and progression. However, the roles of PANoptosis-related genes (PARGs) in the prognosis and immune landscape of head and neck squamous cell carcinoma (HNSCC) remain unclear. Integrated bioinformatics analyses based on the data of HNSCC patients in the TCGA database were conducted. We extracted 48 PARGs expression profile and then conducted differentially expressed analysis, following building a Cox model to predict the survival of HNSCC patients. Subsequently, the relationships between the risk score, immune landscape, chemo-, and immune-therapy responses were analyzed, respectively...
April 29, 2024: Scientific Reports
https://read.qxmd.com/read/38681566/efficacy-and-safety-of-first-line-chemotherapies-for-patients-with-advanced-pancreatic-ductal-adenocarcinoma-a-systematic-review-and-network-meta-analysis
#28
REVIEW
Mao-Ji Kang, Hao-Xin Li, Yu Gan, Cheng Fang, Xiao-Li Yang, Bo Li, Song Su
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, often diagnosed at an advanced stage. Systemic chemotherapy is the primary treatment, but direct comparisons of different regimens are limited. This study conducted a systematic review and network meta-analysis (NMA) to compare the efficacy and safety of various chemotherapy regimens, with the unique advantage of only including Phase III randomized controlled trials (RCTs). METHODS: NMA was conducted regarding the searched phase III RCTs by comparing overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs) of different chemotherapy protocols...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38680003/evaluation-of-the-combined-effect-of-caffeine-and-5-fluorouracil-on-colorectal-cancer-cell-lines
#29
JOURNAL ARTICLE
Fatemeh Khavari, Mohammad Taheri, Hamed Manoochehri, Pejman Molaei, Fatemeh Nouri
BACKGROUND: Cancer is the second leading cause of death in the world. Colorectal cancer is the third leading cause of cancer death. Today, there are several options for treating colorectal cancer such as chemotherapy, surgery, radiotherapy, immunotherapy, and gene therapy. 5-Fluorouracil is known as a suitable candidate for the treatment of various cancers, especially colorectal cancer. However, the use of this drug is limited, so it is usually used in combination with other drugs and agents...
April 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/38678128/anlotinib-inhibits-growth-of-human-esophageal-cancer-te-1-cells-by-negative-regulating-pi3k-akt-signaling-pathway
#30
JOURNAL ARTICLE
Yueli Liu, Fan Li, Qiongyu Wang, Yunfei Zhang, Shuhong Tian, Biao Li
Anlotinib is effective in treatment of many kinds of malignant cancer, but its antineoplastic effects on esophageal cancer remains unclear. This study aims to investigate its impact on esophageal cancer and the underlying mechanisms. Anlotiniband 5-fluorouracil + cisplatin (5-FU + DDP) was administered separately to human esophageal cancer TE- 1 cells tumor xenograft mouse models every 3 days. Tumor size and body weight were measured before each treatment and at the end of the experiment...
April 27, 2024: Discover. Oncology
https://read.qxmd.com/read/38673030/the-performance-of-a-survival-nomogram-and-albumin-bilirubin-grade-as-prognostic-tools-in-advanced-hepatocellular-carcinoma-treated-with-folfox4
#31
JOURNAL ARTICLE
Jirapat Wonglhow, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Arunee Dechaphunkul
BACKGROUND: The ability of the survival nomogram developed in the EACH study and albumin-bilirubin (ALBI) grade to predict the survival of advanced hepatocellular carcinoma (HCC) patients receiving oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) remains unvalidated. Here, we comprehensively evaluated these prognostic tools. METHODS: The survival nomogram and ALBI grade of each patient were assessed, and the area under the receiver operating curve (AUROC) and Harrell's C-index for the risk classification model were calculated...
April 11, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38672597/first-line-lv5fu2-with-or-without-aflibercept-in-patients-with-non-resectable-metastatic-colorectal-cancer-a-randomized-phase-ii-trial-prodige-25-ffcd-folfa
#32
JOURNAL ARTICLE
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio, Matthieu Baconnier, Valérie Lebrun-Ly, Joëlle Egreteau, Faïza Khemissa Akouz, Magali Terme, Côme Lepage, Valérie Boige
Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context. The aim of the study was to determine whether aflibercept could increase the efficacy of fluoropyrimidine monotherapy without increasing toxicity. This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in patients unfit to receive doublet cytotoxic chemotherapy...
April 16, 2024: Cancers
https://read.qxmd.com/read/38669046/pharmacological-targeting-of-histone-h3k27-acetylation-brd4-dependent-induction-of-aldh1a3-for-early-phase-drug-tolerance-of-gastric-cancer
#33
JOURNAL ARTICLE
Jin Lee, Tetsuo Mashima, Naomi Kawata, Noriko Yamamoto, Shun Morino, Saori Inaba, Ayane Nakamura, Koshi Kumagai, Takeru Wakatsuki, Kengo Takeuchi, Kensei Yamaguchi, Hiroyuki Seimiya
Anticancer drug-tolerant persister (DTP) cells at an early phase of chemotherapy reshape refractory tumors. Aldehyde dehydrogenase 1 family member A3 (ALDH1A3) is commonly upregulated by various anticancer drugs in gastric cancer patient-derived cells (PDCs) and promotes tumor growth. However, the mechanism underlying the generation of ALDH1A3-positive DTP cells remains elusive. Here, we investigated the mechanism of ALDH1A3 expression and a combination therapy targeting gastric cancer DTP cells. We found that gastric cancer tissues treated with neoadjuvant chemotherapy (NAC) showed high ALDH1A3 expression...
April 25, 2024: Cancer Res Commun
https://read.qxmd.com/read/38668776/nanoparticle-polymeric-micellar-paclitaxel-versus-paclitaxel-for-patients-with-advanced-gastric-cancer
#34
JOURNAL ARTICLE
Fei-Yu Wang, Xiang-Ming Huang, Yu-Qing Cao, Jie Cao, Jie Ni, Ke Li, Min Lu, Xin-En Huang
BACKGROUND: Nanoparticle polymeric micellar paclitaxel (NPMP) is a novel Cremophor EL (CrEL)-free nanoparticle micellar formulation of paclitaxel. This study evaluated the efficacy and toxicity of NPMP in the treatment of patients with advanced gastric cancer (AGC). METHODS: Patients with histologically confirmed AGC in Jiangsu Cancer Hospital were retrospectively collected and divided into two groups. Patients in group A received NPMP at a total dose of 360 mg/m2 each cycle, and patients in group B were given paclitaxel at a dose of 210 mg/m2 each cycle...
April 26, 2024: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/38668383/possible-involvement-of-long-non-coding-rnas-gnas-as1-and-mir205hg-in-the-modulation-of-5-fluorouracil-chemosensitivity-in-colon-cancer-cells-through-increased-extracellular-release-of-exosomes
#35
JOURNAL ARTICLE
Shamin Azwar, Chin Tat Ng, Siti Yazmin Zahari Sham, Heng Fong Seow, Minhian Chai, Mohd Faizal Ghazali, Mohd Faisal Jabar
A growing number of studies have suggested the involvement of long non-coding RNAs as the key players in not just the initiation and progression of the tumor microenvironment, but also in chemotherapy tolerance. In the present study, generated 5-FU-resistant SW480/DR cells were analyzed via cDNA microarray for its aberrant lncRNAs and mRNAs expression in comparison with the 5-FU-susceptible SW480/DS cells. Among the 126 lncRNAs described, lncRNAs GNAS-AS1 , MIR205HG , and LOC102723721 have been identified to be significantly upregulated, while lncRNs lnc-RP11-597K23...
April 15, 2024: Non-Coding RNA
https://read.qxmd.com/read/38666809/a-phase-ii-study-of-neoadjuvant-chemoradiotherapy-with-docetaxel-cisplatin-and-5-fu-followed-by-surgical-resection-in-the-treatment-of-locally-advanced-esophagogastric-junction-cancer-and-locally-advanced-esophageal-cancer
#36
JOURNAL ARTICLE
Chien-Chih Chen, Hui-Ling Yeh, Cheng-Yeh Chuang, Chung-Ping Hsu
PURPOSE: We conducted a phase II study evaluating chemoradiotherapy in patients with advanced esophageal cancer, using the docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen followed by surgery. The primary purposes of this clinical trial were to assess the efficacy and safety of chemoradiotherapy employing the DCF regimen in the treatment of advanced esophageal cancer. MATERIAL AND METHODS: We enrolled a total of 24 newly diagnosed esophageal cancer patients between April 2015 and November 2017 in this prospective study...
April 22, 2024: Clinics and Practice
https://read.qxmd.com/read/38664331/utility-of-initial-tumor-reduction-as-a-prognostic-factor-in-esophageal-squamous-cell-cancer-patients-undergoing-neoadjuvant-chemotherapy-followed-by-surgery-a-retrospective-cohort-study
#37
JOURNAL ARTICLE
Takaomi Hagi, Osamu Shiraishi, Tomoya Nakanishi, Masashi Kohda, Yoko Hiraki, Hiroaki Kato, Atsushi Yasuda, Masayuki Shinkai, Motohiro Imano, Takushi Yasuda
BACKGROUND: While a neoadjuvant chemotherapy regimen using docetaxel, cisplatin, and 5-fluorouracil (NAC-DCF) is considered the standard treatment for locally advanced esophageal cancer (EC) in Japan, a reliable marker for early prediction of treatment efficacy remains unclear. We investigated the utility of the tumor response after a first course of NAC-DCF as a post-surgery survival predictor in patients with EC. METHODS: We enrolled 150 consecutive patients who underwent NAC-DCF followed by surgery for EC between September 2009 and January 2019...
April 25, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38663403/closed-loop-automated-drug-infusion-regulator-a-clinically-translatable-closed-loop-drug-delivery-system-for-personalized-drug-dosing
#38
JOURNAL ARTICLE
Louis B DeRidder, Kyle A Hare, Aaron Lopes, Josh Jenkins, Nina Fitzgerald, Emmeline MacPherson, Niora Fabian, Josh Morimoto, Jacqueline N Chu, Ameya R Kirtane, Wiam Madani, Keiko Ishida, Johannes L P Kuosmanen, Naomi Zecharias, Christopher M Colangelo, Hen-Wei Huang, Makaya Chilekwa, Nikhil B Lal, Shriya S Srinivasan, Alison M Hayward, Brian M Wolpin, David Trumper, Troy Quast, Douglas A Rubinson, Robert Langer, Giovanni Traverso
BACKGROUND: Dosing of chemotherapies is often calculated according to the weight and/or height of the patient or equations derived from these, such as body surface area (BSA). Such calculations fail to capture intra- and interindividual pharmacokinetic variation, which can lead to order of magnitude variations in systemic chemotherapy levels and thus under- or overdosing of patients. METHODS: We designed and developed a closed-loop drug delivery system that can dynamically adjust its infusion rate to the patient to reach and maintain the drug's target concentration, regardless of a patient's pharmacokinetics (PK)...
April 23, 2024: Med
https://read.qxmd.com/read/38663106/helminth-derived-molecules-improve-5-fluorouracil-treatment-on-experimental-colon-tumorigenesis
#39
JOURNAL ARTICLE
Mónica G Mendoza-Rodríguez, Daniela Medina-Reyes, Cuauhtémoc A Sánchez-Barrera, Karen V Fernández-Muñoz, Verónica García-Castillo, Jorge L Ledesma-Torres, Marisol I González-González, José L Reyes, Carlos Pérez-Plascencia, Miriam Rodríguez-Sosa, Felipe Vaca-Paniagua, Marco A Meraz, Luis I Terrazas
Colorectal cancer (CRC) is one of the most prevalent fatal neoplasias worldwide. Despite efforts to improve the early diagnosis of CRC, the mortality rate of patients is still nearly 50%. The primary treatment strategy for CRC is surgery, which may be accompanied by chemotherapy and radiotherapy. The conventional and first-line chemotherapeutic agent utilized is 5-fluorouracil (5FU). However, it has low efficiency. Combination treatment with leucovorin and oxaliplatin or irinotecan improves the effectiveness of 5FU therapy...
April 24, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38660992/novel-mass-spectrometry-based-assay-for-thymidylate-synthase-activity
#40
JOURNAL ARTICLE
Krzysztof Urbanowicz, Jacek Turyn, Ryszard T Smoleński, Godefridus J Peters
Thymidylate synthase (TS) is an enzyme responsible for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), with the co-substrate 5,10-methylenetetrahydrofolate (5,10-CH2 -THF) as the methyl donor. TS is the only enzyme capable of de novo biosynthesis of dTMP in humans, a nucleotide crucial for DNA synthesis and therefore cell proliferation and survival. As such, TS is a major drug target in chemotherapy by compounds such as 5-fluorouracil. Due to the clinical and physiological importance of TS, the ability to accurately assay its activity is crucial...
April 25, 2024: Nucleosides, Nucleotides & Nucleic Acids
keyword
keyword
100143
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.